Roughly 90 to 100 outsourcing facilities are currently registered with FDA under section 503B, a number that has been climbing steadily for years. Growth is not the hard part of running one. The hard part is that every one of those facilities operates under full cGMP, the same standard a large commercial manufacturer meets, while running close to the opposite production profile: small batches, dozens of SKUs and strengths, and changeovers measured in days rather than quarters. Visual inspection technology built for high-volume, single-SKU commercial lines doesn’t fit that profile, and the FDA’s own inspection record shows it.
What makes a 503B facility structurally different
Section 503B of the Federal Food, Drug, and Cosmetic Act, created by the Drug Quality and Security Act of 2013 in the wake of the 2012 fungal meningitis outbreak tied to compounded drugs, defines an outsourcing facility as a site that compounds sterile drugs, may compound non-sterile drugs, and registers with FDA for that purpose. Unlike a traditional 503A compounding pharmacy, which compounds to a specific patient’s prescription, a 503B facility may compound in bulk without a patient-specific prescription, which is what allows it to supply hospitals, clinics, and health systems directly.
That flexibility comes with a condition FDA has been explicit about: registering as an outsourcing facility does not waive or exempt a facility from cGMP. Outsourcing facilities must register, report the products they compound to FDA twice a year, and report adverse events. FDA’s stated goal is to inspect a newly registered facility within two months. In practice, the agency has fallen well behind that target, which means the sector’s actual quality bar is set less by routine inspection cadence and more by whether a facility’s own program holds up when the inspector eventually arrives.
The FDA’s own inspection record says the gap is real.
A 2025 analysis of FDA inspection records by the Partnership for Safe Medicines found that among outsourcing facilities that had actually been inspected, 96% had been issued a Form 483. Separately, an analysis of 2025 Form 483 observations and warning letters by Dabrico, the hardware manufacturer behind Boon Logic’s DAI-50 inspection platform, identified a consistent pattern specific to 503B facilities: standard operating procedures exist, but commonly lack defined 100% inspection requirements, AQL sampling procedures, operator qualification criteria, defect classification systems, and controlled inspection environments, alongside missing batch record documentation, thin training evidence, and outdated or incomplete defect reference kits.
That is not a story about individual facilities being careless. It is what happens structurally when a cGMP-grade inspection program has to be designed, documented, and kept current across dozens of low-volume SKUs by a quality team sized for a compounding operation, not a commercial manufacturer’s quality department.
Why traditional inspection technology does not fit the 503B production model
Traditional automated visual inspection, rule-based AVI, and supervised AI were built for the opposite economics. Recipe or model development for a single SKU on either approach typically requires weeks to months of engineering work, and the volume needed to justify that investment has historically run above 10 million units a year per SKU. That threshold has excluded orphan products, clinical supplies, and 503B compounded products from automation almost by definition; a facility running twenty SKUs at a few hundred thousand units a year each never clears the bar that makes legacy automated inspection pencil out. We document that volume threshold and where it comes from in why traditional automated inspection was never built for 503B economics.
That leaves manual inspection as the default, and it’s where the structural weakness shows up most directly. It is capable but inconsistent across shifts and inspectors, which is precisely the inspector-variability finding that recurs across 503B inspection reports, and it does not scale cleanly when the same small QA team has to cover dozens of products instead of one.
What the right system needs to do for this profile
- Train and requalify fast enough to match SKU count. AVIS builds a qualification-ready recipe in under 60 minutes on roughly 500 compliant units. That keeps qualification cost proportionate to what a compounding facility actually produces for each SKU, instead of requiring the volume economics that make automation a non-starter for most 503B products.
- Lock and document the model the way a small quality team can actually sustain. A locked, deterministic model with full IQ/OQ/PQ documentation and a 21 CFR Part 11 audit trail on every inspection event and recipe change closes exactly the SOP and documentation deficiencies Dabrico’s review found most often at 503B facilities, without requiring an in-house team large enough to write and maintain dozens of custom AQL and defect-classification procedures by hand.
- Detect defects it has never been shown. Because AVIS trains exclusively on compliant product rather than a labeled defect catalog, it flags a novel defect type the first time it occurs, including a defect specific to one compounded formulation that a defect library built for a different product would never have predicted.
- Fit the facility’s capital profile. Many 503B facilities are independent or hospital-system-owned operations that lack the capital budget of a large CMO. AVIS can be deployed under either a capital purchase or a subscription model, and the subscription path is built for this profile: CMOs, 503Bs, cell and gene therapy manufacturers, and clinical-supply lines where speed and cash preservation matter more than owning the hardware outright.
- Fit the operation physically. The DAI-50’s compact, three-camera footprint and integrated material handling switch between stored recipes in minutes, with no model rebuilding or re-qualification, matching a facility that might run six, ten, or twenty different compounded sterile products through the same inspection station in a given week.
The decision
With the outsourcing facility sector still growing and inspection scrutiny rising rather than falling, the compounding industry’s quality bar is converging with commercial manufacturing’s faster than most 503B inspection programs have kept pace. The facility that can show a locked, documented, audit-trailed inspection model, sized and priced for a compounding operation rather than a blockbuster commercial line, is the one that comes through its next FDA inspection clean. The facility still running inspection on inconsistent manual coverage, or waiting for volume it will never hit to justify legacy automation, is the one providing an explanation for a Form 483 finding it saw coming.
See What Is AVIS? | Read The Gap in Vision Inspection Systems for Pharmaceuticals | Request a Demo
